Medincell says Teva wins FDA approval for WELTRUZA olanzapine monthly injection
TEVA•The FDA approved Teva’s once-monthly WELTRUZA injection for adults with schizophrenia; a U.S. launch is expected in coming weeks, and the approval triggers a $4 million milestone payment to Medincell.
1. Approval and payments
The FDA cleared Teva’s WELTRUZA (olanzapine) once-monthly subcutaneous long-acting injection for adults with schizophrenia, using Medincell technology. Medincell will receive mid- to high-single-digit royalties on worldwide net sales, and the approval triggers a $4 million milestone payment; additional commercial milestones total up to $105 million.
